New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia

Author:   W. Hiddemann ,  R. Mertelsmann ,  W. Hiddermann
Publisher:   Springer-Verlag Berlin and Heidelberg GmbH & Co. KG
ISBN:  

9783540526131


Pages:   52
Publication Date:   22 August 1990
Format:   Paperback
Availability:   Out of stock   Availability explained
The supplier is temporarily out of stock of this item. It will be ordered for you on backorder and shipped when it becomes available.

Our Price $50.03 Quantity:  
Add to Cart

Share |

New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia


Add your own review!

Overview

This book provides a unique overview of the current applications of aclacinomycin A in malignant haematologic disorders, as single-agent therapy or together with other agents in combination regiments. Accounts are given of its action in myelodysplastic syndromes and of its efficacy in acute myeloid leukemias for the latter, one chapter presents the results of single-agent therapy in older patients, while four other studies describe the efficacy of aclacinomycin A combined with conventional or intermediate-dose cutosine arabinoside or etoposide in relapsed or refractory acute myeloid leukemia.

Full Product Details

Author:   W. Hiddemann ,  R. Mertelsmann ,  W. Hiddermann
Publisher:   Springer-Verlag Berlin and Heidelberg GmbH & Co. KG
Imprint:   Springer-Verlag Berlin and Heidelberg GmbH & Co. K
Dimensions:   Width: 15.50cm , Height: 0.30cm , Length: 23.50cm
Weight:   0.140kg
ISBN:  

9783540526131


ISBN 10:   3540526137
Pages:   52
Publication Date:   22 August 1990
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Paperback
Publisher's Status:   Active
Availability:   Out of stock   Availability explained
The supplier is temporarily out of stock of this item. It will be ordered for you on backorder and shipped when it becomes available.

Table of Contents

Aclarubicin in Single Agent and Combined Chemotherapy of Adult Acute Myeloid Leukemia.- Low-Dose Aclacinomycin and Intermediate-Dose Cytosine - Arabinoside in Relapsed and Refractory Acute Myelogenous Leukemia.- Aclarubicin Plus Cytosine Arabinoside Versus Daunorubicin Plus Cytosine Arabinoside in De Novo Acute Myelocytic Leukemia: A Danish National Trial.- Fractionated Aclacinomycin in Combination with Cytosine Arabinoside and Etoposide for Remission Induction in Adult Acute Myeloid Leukemia.- Aclarubicin in the Treatment of Refractory Acute Leukemias.- Aclacinomycin A/Etoposide Combination Therapy for Advanced Relapsed Acute Myeloid Leukemia: Results of a Pilot Study of the Arbeitsgemeinschaft Internistische Onkologie.- Low-Dose Aclacinomycin A in Myelodysplastic Syndromes and Subsequent Acute Myelogenous Leukemia: A Phase II Study.

Reviews

Author Information

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions
Latest Reading Guide

MRG2025CC

 

Shopping Cart
Your cart is empty
Shopping cart
Mailing List